New Promising Diagnostic Signatures in Histopathological Diagnosis

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 390

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pathology, County Clinical Emergency Hospital, Faculty of Medicine and Pharmacy, University of Oradea, 1 December Sq. No. 10, 410087 Oradea, Romania
Interests: molecular diagnosis; biomarkers; histopathology; immune response

Special Issue Information

Dear Colleagues,

Histopathological diagnosis has been at the backbone of clinical medicine for over a century, as the microscopic examination of tissue samples can provide detailed insights into the nature, origin, and progression of diseases. Recent advancements in molecular biology, imaging techniques, and data analytics have led to the discovery of new diagnostic signatures. Some general areas where these new promising signatures have been emerging: artificial intelligence and machine learning, immunohistochemistry (IHC) markers, molecular diagnostics, digital pathology, liquid biopsies, quantitative histopathology, deep learning, and convolutional neural networks.

It's crucial to understand that while these advancements hold promise, they also come with challenges. The interpretation of complex data sets, integration of various diagnostic tools, and establishing robustness and reproducibility are all areas that need further work. The integration of various diagnostic signatures from multiple sources (like combining genomic data with histopathological images) will likely provide even more refined and accurate diagnostic tools for clinicians.

The purpose of this Special Issue is to explore the new frontiers in pathology as well as the integration of these new perspectives for the benefit of the patient.

Prof. Dr. Ovidiu Laurean Pop
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • AI
  • IHC
  • digital pathology
  • liquid biopsies
  • deep learning
  • neural network

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 953 KiB  
Article
Is There an Immunohistochemical PD-L1 Cut-Off Point That Serves as a Prognostic Indicator for Large B-Cell Lymphomas?
by Selcuk Cin, Suat Hilal Aki, Tugrul Elverdi, Deniz Ozmen and Ayse Salihoglu
Diagnostics 2024, 14(11), 1167; https://doi.org/10.3390/diagnostics14111167 - 31 May 2024
Abstract
The aim of this study is to investigate whether there is a cut-off value for PD-L1 expression in large B-cell lymphomas that predicts prognosis, and to clarify the relationship between PD-L1 expression and histopathological as well as clinical parameters. The study included a [...] Read more.
The aim of this study is to investigate whether there is a cut-off value for PD-L1 expression in large B-cell lymphomas that predicts prognosis, and to clarify the relationship between PD-L1 expression and histopathological as well as clinical parameters. The study included a total of 130 patients who were diagnosed with large B-cell lymphoma at Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Pathology Department. Biopsy samples were assessed using the PD-L1 immunohistochemical antibody (Dako, 22C3 clone). The patients had a mean age of 54 ± 17 years, with a median age of 56 years. No statistically significant difference was observed between the groups in terms of survival when the 30% cut-off value was used. However, a noteworthy discrepancy in survival became apparent when the cut-off point was established at 70%. Among the diffuse large B-cell lymphoma-not otherwise specified (DLBCL-NOS) category, the activated B-cell-like (ABC-like) phenotype showed higher PD-L1 expression compared to the germinal center B-cell-like (GCB-like) phenotype. Immunohistochemical PD-L1 expression emerged as a prognostic factor, particularly significant in the ABC-like phenotype. Full article
(This article belongs to the Special Issue New Promising Diagnostic Signatures in Histopathological Diagnosis)
Back to TopTop